Read + Share
Bomze D, Mutti L, Goldman A, Markel G, et al. Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining
immune checkpoint inhibition with chemotherapy. Lancet Oncol 2022;23:e245.
PMID: 35654062
|
 |
|
Bomze D, Mutti L, Goldman A, Markel G, et al. Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining
immune checkpoint inhibition with chemotherapy. Lancet Oncol 2022;23:e245.
PMID: 35654062
|
|
|
|